Introducing the SYMPHONY™ Breast Cancer Profile using

Paraffin Embedded Tissue.

Now there is an additional way to obtain the world’s most complete genomic profile for your breast cancer patients. Only SYMPHONY combines its unique, pure biology with the convenience of using paraffin embedded tissue.

And, only SYMPHONY can deliver these important benefits

to your practice:

Comprehensive Tumor Profiling

SYMPHONY includes four assays to support your treatment decisions: MammaPrint® determines the risk of recurrence. BluePrint™ determines molecular subtypes and TargetPrint® determines ER, PR and HER2 status. TheraPrint™ identifies alternative types of therapy for metastatic disease. Collectively, SYMPHONY provides you with the most complete breast cancer tumor profiling available on the market today.

Clear Direction for Indeterminate Cases

SYMPHONY gives you key additional information to help with treatment decisions even for cases that have been otherwise classified as indeterminate, such as grade 2, small tumors, HER2 and/or lymph node positive.

100% Definitive Results

SYMPHONY signatures were developed by analyzing all 25,000 genes of the human genome to identify those genes that regulate breast cancer including genes in each of the 7 metastatic pathways. Over 5,000 patients enrolled in 17 clinical trials worldwide have validated the clinical utility of our assays. You will receive a clear, accurate result each and every time you order SYMPHONY.

Unmatched Convenience

SYMPHONY now adds the convenience of using paraffin embedded tissue to services such as On Demand testing and online ordering. What’s more, our new OncoBank Service enables you to store your patients’ tissue for future testing.

For breast cancer treatment information that works in concert with the way you practice, SYMPHONY is the pure choice for biology and convenience. To learn more, contact your Agendia representative or visit us online at agendia.com.